SpaceX IPO is the biggest IPO in stock market history. Join the conversation.Click here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksVictrex Regulatory News (VCT)

Share Price Information for Victrex (VCT)

Share Price is delayed by 15 minutes
Get Live Data
620.00    9.00 (1.47%)
Bid:
621.00
Ask:
623.00
Spread: 2.00 (0.322%)
Market Cap: £540.17m
VCT Live PriceLast checked at - London Stock Exchange

Intraday Victrex Share Chart

Trading Statement

9 Oct 2014 07:00

RNS Number : 8130T
Victrex PLC
09 October 2014
 



 

 

 

 

9 October 2014

 

Victrex plc - Pre-close trading statement

 

"A strong finish to 2014 - growth momentum continues"

 

Victrex plc, an innovative world leader in high performance polymer solutions, today releases its pre-close trading statement for the financial year ended 30 September 2014, ahead of its preliminary results on Tuesday 9 December 2014.

 

Victrex delivered a strong finish to 2014, with the Group continuing its volume growth momentum from the first half year across our strategic markets of Automotive, Aerospace, Energy, Electronics and Medical. Full year Group sales volume of 3,551 tonnes increased by 22% (2013: 2,920 tonnes), with second half year sales volume of 1,967 tonnes increasing by 29% on last year (H2 2013: 1,528 tonnes). Although sales volumes were particularly strong, our profit expectations remain largely unchanged.

 

The strong volume performance in our Victrex Polymer Solutions (VPS) business reflects core growth and higher than expected volumes in the second half year from Consumer Electronics. Stripping out sales volumes across the entire Electronics segment, second half year sales volume increased by 6% on the prior year. Our higher margin Speciality Products business, including Aptiv film, again performed well during the year. With continued growth in Aptiv, we will bring an additional production line on stream during the first half of our new financial year.

 

In our higher margin Invibio medical business, full year revenue increased by 5% to £53.4m (2013: £50.8m), reflecting steady improvement in the Spine market. The focus for 2015 remains the roll-out of new products into the Spine market, with regulatory applications lodged in the US and Europe for the innovative PEEK-OPTIMA® HA-Enhanced product, which enhances bone-on-growth. Pending regulatory approval, adoption and roll-out will commence during the first half.

 

As we start our new financial year, our growth momentum remains positive. Although currency headwinds remain considerable in 2015, our forthcoming new PEEK and Aptiv film capacity, technical excellence and marketing know-how keep us well placed to continue driving growth and creating value, in line with our long term strategy.

 

Enquiries:

 

Victrex plc:

Andrew Hanson, Head of Investor Relations & Communications +44 (0) 1253 898121

Louisa Burdett, Group Finance Director +44 (0) 1253 897700

 

Pendomer Communications:

Charles Armitstead / Rebecca Hall +44 (0) 203 603 5220

 

About Victrex:

Victrex is an innovative world leader in high performance polymer solutions focused on the strategic markets of Aerospace, Automotive, Electronics, Energy and Medical. Every day, millions of people rely on products or applications which contain our polymers, from smartphones, aeroplanes and cars to oil & gas operations and medical devices. With over 35 years' experience, we are investing in technical excellence to deliver new and leading edge solutions to our customers and our markets, and to drive value for our shareholders. Visit www.victrexplc.com

 

Investor and analyst call:

A call for investors and analysts will be held today, Thursday 9 October 08.30 UK time. For dial in details contact Rebecca Hall at Pendomer on +44 (0) 203 603 5220 or Rebecca.Hall@pendomer.com

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
TSTUGGBAUUPCGCR
Date   Source Headline
1st Dec 201712:51 pmRNSBlock listing Interim Review
30th Nov 20171:41 pmRNSTotal Voting Rights
27th Nov 201711:20 amRNSAdditional Listing
17th Nov 20173:57 pmRNSDirector/PDMR Shareholding
31st Oct 20179:41 amRNSTotal Voting Rights
17th Oct 20173:29 pmRNSDirector/PDMR Shareholding
29th Sep 201710:31 amRNSTotal Voting Rights
19th Sep 20172:59 pmRNSDirector/PDMR Shareholding
4th Sep 20177:01 amRNSCEO-designate update
4th Sep 20177:00 amRNSReduction in effective tax rate
31st Aug 20173:31 pmRNSTotal Voting Rights
17th Aug 201711:39 amRNSDirector/PDMR Shareholding
31st Jul 201710:36 amRNSTotal Voting Rights
25th Jul 20177:00 amRNSTrading Statement
18th Jul 20172:10 pmRNSDirector/PDMR Shareholding
30th Jun 20172:09 pmRNSTotal Voting Rights
19th Jun 20174:18 pmRNSDirector/PDMR Shareholding
1st Jun 20179:51 amRNSBlock listing Interim Review
31st May 20179:22 amRNSTotal Voting Rights
31st May 20179:05 amRNSHolding(s) in Company
19th May 20179:39 amRNSAdditional Listing
18th May 201710:23 amRNSDirector/PDMR Shareholding
15th May 20177:00 amRNSHalf-year Report
28th Apr 20172:39 pmRNSTotal Voting Rights
19th Apr 20172:17 pmRNSDirector/PDMR Shareholding
19th Apr 20177:57 amRNSDirectorate Change
6th Apr 20177:00 amRNSAcquisition
31st Mar 201710:32 amRNSTotal Voting Rights
28th Mar 20177:00 amRNSCapital Markets Day
24th Mar 20172:44 pmRNSHolding(s) in Company
17th Mar 20172:12 pmRNSDirector/PDMR Shareholding
17th Mar 20179:34 amRNSHolding(s) in Company
14th Mar 201710:56 amRNSHolding(s) in Company
9th Mar 20174:33 pmRNSHolding(s) in Company
28th Feb 201710:49 amRNSTotal Voting Rights
17th Feb 201711:30 amRNSDirector/PDMR Shareholding
8th Feb 20171:59 pmRNSResult of AGM
8th Feb 20179:00 amRNSAudit Tender Notification
8th Feb 20177:00 amRNSAGM Statement
31st Jan 20173:54 pmRNSTotal Voting Rights
17th Jan 20172:52 pmRNSDirector/PDMR Shareholding
5th Jan 201711:31 amRNSAnnual Financial Report
30th Dec 201611:37 amRNSHolding(s) in Company
30th Dec 201610:00 amRNSTotal Voting Rights
21st Dec 20169:14 amRNSDirector Declaration
19th Dec 201612:54 pmRNSDirector/PDMR Shareholding
15th Dec 20169:02 amRNSDirector Declaration
8th Dec 20163:41 pmRNSDirector/PDMR Shareholding
6th Dec 20167:00 amRNSFinal Results
1st Dec 201611:53 amRNSBlock listing Interim Review

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.